Target Price | CHF729.46 |
Price | CHF792.00 |
Deviation | 7.90% |
Number of Estimates | 13 |
13 Analysts have issued a price target Swiss Life 2026 . The average Swiss Life target price is CHF729.46. This is 7.90% lower than the current stock price. The highest price target is CHF805.00 1.64% , the lowest is CHF575.00 27.40% . | |
A rating was issued by 15 analysts: 5 Analysts recommend Swiss Life to buy, 5 to hold and 5 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Swiss Life stock has an average upside potential 2026 of 7.90% . |
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion CHF | 15.28 | 18.17 |
0.28% | 18.92% | |
Net Margin | 7.92% | 7.00% |
13.94% | 11.61% |
5 Analysts have issued a sales forecast Swiss Life 2025 . The average Swiss Life sales estimate is CHF18.2b . This is 18.93% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF21.2b 38.51% , the lowest is CHF8.9b 41.49% .
This results in the following potential growth metrics:
2024 | CHF15.3b | 0.28% |
---|---|---|
2025 | CHF18.2b | 18.92% |
2026 | CHF18.5b | 1.67% |
2027 | CHF20.7b | 12.13% |
2028 | CHF21.0b | 1.44% |
10 Swiss Life Analysts have issued a net profit forecast 2025. The average Swiss Life net profit estimate is CHF1.3b . This is 4.37% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF1.4b 12.23% , the lowest is CHF1.2b 0.53% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF1.2b | 14.25% |
---|---|---|
2025 | CHF1.3b | 5.05% |
2026 | CHF1.4b | 6.52% |
2027 | CHF1.4b | 6.10% |
2028 | CHF1.5b | 7.21% |
2029 | CHF1.5b | 2.84% |
2024 | 7.92% | 13.94% |
---|---|---|
2025 | 7.00% | 11.61% |
2026 | 7.33% | 4.71% |
2027 | 6.94% | 5.32% |
2028 | 7.33% | 5.62% |
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 42.41 | 44.55 |
14.25% | 5.05% | |
P/E | 17.78 | |
EV/Sales | 1.77 |
10 Analysts have issued a Swiss Life forecast for earnings per share. The average Swiss Life EPS is CHF44.55 . This is 4.36% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF47.91 12.23% , the lowest is CHF42.46 0.54% .
This results in the following potential growth metrics and future valuations:
2024 | CHF42.41 | 14.25% |
---|---|---|
2025 | CHF44.55 | 5.05% |
2026 | CHF47.46 | 6.53% |
2027 | CHF50.35 | 6.09% |
2028 | CHF53.99 | 7.23% |
2029 | CHF52.45 | 2.85% |
Current | 18.55 | 14.22% |
---|---|---|
2025 | 17.78 | 4.15% |
2026 | 16.69 | 6.13% |
2027 | 15.73 | 5.75% |
2028 | 14.67 | 6.74% |
2029 | 15.10 | 2.93% |
Based on analysts' sales estimates for 2025, the Swiss Life stock is valued at an EV/Sales of 1.77 and an P/S ratio of 1.24 .
This results in the following potential growth metrics and future valuations:
Current | 2.10 | 0.48% |
---|---|---|
2025 | 1.77 | 15.87% |
2026 | 1.74 | 1.64% |
2027 | 1.55 | 10.81% |
2028 | 1.53 | 1.42% |
Current | 1.48 | 1.70% |
---|---|---|
2025 | 1.24 | 15.92% |
2026 | 1.22 | 1.64% |
2027 | 1.09 | 10.82% |
2028 | 1.08 | 1.41% |
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Feb 05 2025 |
BERENBERG |
Buy
➜
Buy
|
Unchanged | Dec 12 2024 |
BNP PARIBAS EXANE |
Outperform
➜
Outperform
|
Unchanged | Dec 08 2024 |
HSBC |
Hold
➜
Hold
|
Unchanged | Nov 24 2024 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Mar 31 2025 |
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Feb 05 2025 |
Unchanged
BERENBERG:
Buy
➜
Buy
|
Dec 12 2024 |
Unchanged
BNP PARIBAS EXANE:
Outperform
➜
Outperform
|
Dec 08 2024 |
Unchanged
HSBC:
Hold
➜
Hold
|
Nov 24 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.